 | *Read Disclaimer Sponsored Content |
| January 21, 2026 | Unsubscribe | Hello! | Following our alert this morning, NNVC opened at 1.16 and so far, rallied to a high of 1.21. | NNVC has been building a solid base for the past two months around current levels. | We have profiled this opportunity previously after which it rallied upwards of +35%, +53%, +44%. | For instance, in December, NNVC rallied +36% from current levels with a similar chart setup. | NNVC has a 20 and 50 day moving average of 1.18 and 1.27. | A breakout and close above these levels could present increased upside potential. | NNVC has a 200 day moving average of 1.41, +21% from today's open. | Above that, November's high of 2.23 is +92% from today's open. | As the company explained in their most recent press release from January: | NanoViricides' Current Antiviral Drugs Pipeline: NV-387, A Revolutionary Broad-Spectrum Antiviral with Multiple Indications | "The Phase II clinical stage revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections. Over 90% of human pathogenic viruses use heparan sulfate features, which NV-387 copies and presents to fool the virus." |
|
| "NV-387 is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle using the same features that the virus uses to infect cells." |
|
| "Viruses cannot escape NV-387 despite all the changes in the field because the virus still needs to bind to heparan-sulfate like features in order to cause productive pathogenic infection. NV-387 presents copious amounts of these binding sites to the virus, thereby engulfing the virus particle. Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans - the very characteristic that NV-387 emulates." |
|
| "This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS." |
|
| NV-387 for Influenza and Bird Flu | "NV-387 was found to be substantially superior to Tamiflu as well as Xofluza against Influenza virus A/H3N2 in animal model studies of Influenza A/H3N2 lethal lung infection [2]." |
|
| "Further, should Bird Flu H5N1 turn into a human outbreak, variants resistance to Tamiflu and Xofluza can be expected to generate rapidly [3]. NV-387 would be the ideal drug to combat the resulting outbreak, epidemic or pandemic. The causative influenza virus would not be able to escape NV-387 [4]." |
|
| NV-387 for All Respiratory Viral Infections | "A Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI) is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease." |
|
| "NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections." |
|
| "There is no treatment approved for RSV, an important disease for infants and children in early life, as well as for geriatric subjects." |
|
| In addition, yesterday, the company announced: | NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference | "SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will participate in the DealFlow Discovery Conference, taking place January 28th and 29th, 2026." |
|
| "Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, January 29th at 11:00 am ET, and will be available for one-on-one investor meetings throughout the event." |
|
| "Event Details: | Conference: 3rd Annual DealFlow Discovery Conference Venue: The Borgata Hotel, Casino & Spa Location: Atlantic City, NJ" Date: January 28th-29th, 2026
| Here are a couple of the things to keep in mind for upside potential. | Look for NNVC to make higher lows and higher highs. That is often the first sign of a more sustainable uptrend. | A strong close near the highs could help confirm a potential new leg higher. | A rally and close above the 20- and 50-day moving averages could result in increased upside. | In addition, NNVC has a RSI of 48 – showing upside potential. | We are continuing to monitor NNVC for a sustainable breakout higher. | Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, Website, Chart | | Happy Trading! | | SmallCapStocks Team | | Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. | | DISCLAIMER: | You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the "Publisher"). The information (collectively the "Advertisement") disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender's phone number with the word STOP or HELP for help. | The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. | The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. | Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 1/12/26 for the distribution of this advertisement about NNVC dated 1/21/26. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 12/30/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/29/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/16/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated a total of eight thousand dollars by bank wire transfer on 6/20/25 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated seven thousand dollars by bank wire transfer on 2/20/25 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. | You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@SmallCapStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: | www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy | By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. |
|
Tidak ada komentar:
Posting Komentar